VIDEO: Latest developments in prostate cancer treatment

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Radiopharmaceuticals are probably the biggest development. They’re the newest approval and a sort of new class of drugs, so specifically, lutetium-177-PSMA-617. But, you know, beyond this one agent, there’s a huge amount of research now looking at combinations with immunotherapy or [poly (ADP-ribose) polymerase (PARP)] inhibitors or combinations of radiopharmaceuticals and how to make newer, potentially even more effective radiopharmaceuticals by switching out the particle or how the target is identified.

And, of course, new targets, since not every prostate cancer patient expresses PSMA. So, there was a lot of excitement about this new drug above and beyond the one drug, but as sort of a whole new frontier.